CP CRANBURY PHARMACEUTICALS

88418271 | Trademark

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.
Filed May 7, 2019
Serial No. 88418271
Examining Attorney LAILA SABAGH
Class Prescription and non-prescription pharmaceutical medicines and preparations for the treatment of cold and allergy symptoms, respiratory disease, asthma and chronic lung disease, upper respiratory symptoms, coughs, central nervous system disorders, namely, narcolepsy and attention deficit hyperactivity disorder, for the treatment of autism, schizophrenia, bipolar disorder, convulsions, epilepsy, nausea, vomiting, pruritus, for inducing sedation, for pain relief, and for anti-inflammation; dietary supplements; nutritional supplements; vitamins; nutritional supplements in the nature of nutriceuticals for use in treating nutritional deficiencies and as dietary supplements; 006; 018; 044; 046; 051; 052
CP CRANBURY PHARMACEUTICALS
Case Type Trademark
Status Abandoned because no Statement of Use or Extension Request timely filed after Notice of Allowance was issued. To view all documents in this file, click on the Trademark Document Retrieval link at the top of this page.
Opposition 88418271
In re CRANBURY PHARMACEUTICALS
  • CRANBURY PHARMACEUTICALS;
Last Updated: 2 months, 3 weeks ago
Filing Date # Docket Text
12/26/2023
12/26/2023
12/26/2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
12/25/2023ABANDONMENT - NO USE STATEMENT FILED
5/18/2023
5/18/2023
5/18/2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
5/17/2023SOU EXTENSION 5 GRANTED
5/12/2023
5/12/2023SOU TEAS EXTENSION RECEIVED
5/12/2023SOU EXTENSION 5 FILED
11/5/2022
11/5/2022
11/5/2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/3/2022
11/3/2022SOU TEAS EXTENSION RECEIVED
11/3/2022SOU EXTENSION 4 FILED
11/3/2022SOU EXTENSION 4 GRANTED
4/29/2022
4/29/2022
4/29/2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
4/27/2022
4/27/2022SOU TEAS EXTENSION RECEIVED
4/27/2022SOU EXTENSION 3 FILED
4/27/2022SOU EXTENSION 3 GRANTED
11/25/2021
11/25/2021
11/25/2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
11/23/2021
11/23/2021SOU TEAS EXTENSION RECEIVED
11/23/2021SOU EXTENSION 2 FILED
11/23/2021SOU EXTENSION 2 GRANTED
6/23/2021
6/23/2021
6/23/2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
6/22/2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
6/22/2021SOU EXTENSION 1 GRANTED
5/27/2021
5/27/2021
5/27/2021TEAS PETITION TO REVIVE RECEIVED
5/27/2021PETITION TO REVIVE-GRANTED
5/27/2021SOU EXTENSION RECEIVED WITH TEAS PETITION
5/27/2021NOTICE OF REVIVAL - E-MAILED
5/24/2021SOU EXTENSION 1 FILED
11/24/2020
11/24/2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
9/29/2020
9/29/2020PUBLISHED FOR OPPOSITION
9/29/2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
9/9/2020
9/9/2020
9/9/2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
8/26/2020
8/25/2020APPROVED FOR PUB - PRINCIPAL REGISTER
8/25/2020EXPARTE APPEAL TERMINATED
8/21/2020
8/20/2020CORRESPONDENCE RECEIVED IN LAW OFFICE
8/20/2020TEAS/EMAIL CORRESPONDENCE ENTERED
8/18/2020
8/18/2020EXPARTE APPEAL RECEIVED AT TTAB
8/18/2020JURISDICTION RESTORED TO EXAMINING ATTORNEY
8/18/2020EX PARTE APPEAL-INSTITUTED
8/18/2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
8/18/2020TTAB Proceeding Filed: In re CRANBURY PHARMACEUTICALS, 88418271
2/19/2020
2/19/2020FINAL REFUSAL WRITTEN
2/19/2020FINAL REFUSAL E-MAILED
2/19/2020NOTIFICATION OF FINAL REFUSAL EMAILED
1/30/2020
1/29/2020ASSIGNED TO LIE
1/29/2020CORRESPONDENCE RECEIVED IN LAW OFFICE
1/29/2020TEAS/EMAIL CORRESPONDENCE ENTERED
1/23/2020
1/23/2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
7/25/2019
7/25/2019PRIORITY ACTION WRITTEN
7/25/2019PRIORITY ACTION WRITTEN
7/25/2019PRIORITY ACTION E-MAILED
7/25/2019NOTIFICATION OF PRIORITY ACTION E-MAILED
7/23/2019
7/23/2019
7/22/2019ASSIGNED TO EXAMINER
5/23/2019
5/23/2019NOTICE OF DESIGN SEARCH CODE E-MAILED
5/22/2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
5/10/2019NEW APPLICATION ENTERED
5/7/2019
5/7/2019